Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label aripiprazole safety and tolerability study in pediatric Tourette's disorder
2012-003489-42Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of aripiprazole in Tourette syndrome (TS), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Safety and tolerability. Started Jan 2013; status: completed.
02
Drugs
aripiprazole
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on 2012-003489-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003489-42.